anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hyperbaric oxygen (HBO) reduces neuropathic pain, promote healing of hypoxic, chronic wounds and sores caused by radiation therapy. Nitric oxide (NO) is a contributing factor to the prolonged anti-nociceptive effect of HBO treatment. In addition, HBO stimulates the formation of reactive oxygen and nitrogen forms, reduces beta-2 integrin function, and reduces contact of leukocytes to the endothelial surface of the capillaries, improves microcirculation and causes decreased monocyte chemokine synthesis. It is the interaction of these mechanisms involved in HBO's anti-inflammatory effect. How HBO reduces pain and inflammation in humans has not been established. In healthy subjects, investigators have shown that HBO has a reducing effect on the mechanism, which at the level the of spinal cord amplifies the number and and the extension of pain impulses. Subjects who were given HBO therapy initially developed significantly less secondary hyperalgesia than the control group several weeks later by the new heat injury suggesting a protective, preconditioning effect. As in the previous experiment (NCT02025686) preconditioning effects will be assessed by means of measurements of thermal thresholds, pin-prick thresholds, erythema indices and secondary hyperalgesic areas (i.e. area under the curve per minute). Similarly,differences in the sequence of sessions (i.e. first session HBO;second session ambient pressure condition or first session ambient pressure condition;second session HBO) will be analyzed accordingly. In an improved blinded study design investigators will now investigate the effect of HBO treatment using the same cutaneous heat injury model, as in the first study. Investigators expect to finally be able to confirm previous results thereby improving treatment of severe pain conditions.
This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
The tracking system uses an electronic labels (32,34,36,37) which can be read by a reader. A central database (2) records different data relating to the different objects present, deriving information from electronic label readers at terminals, linked via a network.  The system for following sanitary operations in a hospital includes the use of an electronic label (32,34,36,37) which can be read by a reader, associated with each tracked element. It includes a central database (2) for recording different data relating to the different objects present, and a server (6) connected to the central database. An internal and external network (8) is connected to the server, and terminals (10,20) are connected to the server via the internal network to transmit and record data relating to the elements present in the central database. A reader (12,22) is associated with each terminal for reading the electronic labels. Each electronic label includes a memory to record data concerning the element to which it is attached, and the identification code of the label.
An ophthalmically acceptable vehicle includes an aqueous suspension having a first viscosity. The suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. The polymer has average particle size of not more than about 50 μm in equivalent spherical diameter. The vehicle includes a second polymer that allows the carboxyl-containing polymer to remain suspended. Upon contact with tear fluid, the vehicle gels to a second viscosity which is greater than the first viscosity. A method of administering a medicament to the eye of a subject includes applying a composition that includes this ophthalmically acceptable vehicle and a medicament contained for treatment of a disease or disorder for which ophthalmic delivery is indicated. The medicament is released from the vehicle in a sustained release manner.
The present invention demonstrates for the first time that FAT1 plays an important role in modulating PDCD4 expression, which in turn regulates AP-1 dependent transcription, controls processes crucial for migration and invasion in cancer cells, controls induction of a pro-inflammatory micro environment in cancer cells. The study illustrates a link between inflammation and cancer in cells or in a subject. This work highlights the importance of FAT1 in the induction of the cellular pathways of migration and invasion, proteolysis of the ECM and the expression of pro-inflammatory molecules leading to a favorable micro environment for tumor and cancer progression. The present invention also provides the use of FAT1 in regulating neoplastic phenotypes and genotypes including invasiveness and inflammatory micro environment of the cancer cells by acting as a novel apical regulator of a signaling pathway by affecting the AP1 transcriptional activity, affecting the property of both cell migration and invasion and at the same time affecting the expression of inflammatory modulators. The present invention also identifies a novel regulatory pathway for inflammatory mediators and inflammatory cellular responses via PDCD4 and AP1. The invention describes a pathway for the upregulation of inflammatory processes as such, and hence a means of regulating inflammatory pathologies in general.
The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
The invention relates to a dentifrice for whitening teeth and preparation method. The dentifrice is constituted of eatable silica dioxide, sodium bicarbonate, trimerization sodium phosphate, sodium glutamate, cyclohexyl amino sodium sulphonate, sodium saccharin, natural menthol, mint powder extract, cornstarch and starch enzyme. These material are comminuted, screened, mixed equably and packaged at last. The application method is using cotton swab dipping dentifrice and cleaning inner and outer teeth surface slightly emphatically everyday. The using dosage is about 1-1.5 g every tooth. After 4-7 days the teeth is clean. The excellence of the dentifrice is capable of removing teeth bacterial plaque, special teeth bacterial plaque (dental fluorosis), yellow parenchyma and halitosis, growing gum, diminishing inflammation, sterilizing, preventing oral disease and whitening teeth for long time use.
A definite causal link between pegylated liposomal doxorubicin (PLD) and kidney-limited thrombotic microangiopathy (TMA) remains unestablished. Here, we report 2 cases of PLD-induced kidney-limited TMA, 1 in a patient with myxofibrosarcoma and the other in a patient with liposarcoma. The 2 patients received a high cumulative dose of PLD, and both presented with a rise in serum creatinine and proteinuria. Kidney biopsy revealed TMA with chronic mesangiolysis and capillary wall double contouring. Neither patient had concomitant exposure to TMA-causing drugs, such as gemcitabine, anti-vascular endothelial growth factor agents, or mammalian target of rapamycin inhibitors. The work-up for secondary causes of TMA was negative in both patients. The cessation of PLD therapy led to improvement or stabilization in serum creatinine and proteinuria in both patients. These 2 cases provide a clear causal link between PLD and kidney-limited TMA. The high cumulative dose of PLD increases the risk of kidney TMA. Early recognition of PLD-induced kidney TMA can lead to timely cessation of PLD therapy and potentially preserve kidney function.
Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.
The invention can be used in medicine and veterinary science to create a drug that is effective in the treatment of cancerous diseases in humans and animals. The modified anticomplementary oligonucleotides with anticancer properties and the method for producing same are characterized in that a mixture of polynucleotide hydrolysis products is used as oligonucleotides, and modification is carried out by changing the charges of the molecules of the nucleotide bases to an opposite charge so that said bases acquire anticomplementary properties. The polynucleotides are hydrolyzed using natural and synthetic nucleases and acid or alkaline hydrolysis, and the structure is modified by acylation of the aminogroups of the mononucleotides in the oligonucleotide structure using dicarboxylic acid anhydrides or by alkylation using halogen carboxylic acids. The claimed mixture has the ability to bind selectively to mRNA and thus stop the synthesis of protein in cancer cells, similar to the action of microRNA. Since the drug is able to adapt to an organism, it can be used without risk of a tumour becoming habituated to the drug. The agent has a broad spectrum of action, low toxicity and is suitable for industrial production as well as being effective at all stages in the cancer process.
Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.
OBJECTIVE: Thumb osteoarthritis is a frequent pathology, mainly affecting the elderly. The surgical treatment initially described and having proved its worth is total trapeziectomy. Since the advent of trapeziometacarpal prostheses, several studies showed the non-inferiority of this technique on clinical criteria, with superiority in bone sparing, although neither technique demonstrated overall superiority. We therefore examined the specific complications of each surgical technique by analyzing their nature and prevalence through a review of the literature to compare them on these new parameters.
METHODS: Seventy-four of the 320 articles reviewed were included, 38 of which concerned trapeziectomy, and 36 concerned prostheses, for a total of 4,865 patients. They were original studies, involving adults undergoing trapeziometacarpal arthroplasty or trapeziectomy, published after 2015, reporting at least one well-described complication.
RESULTS: 6.13% of trapeziectomies presented severe complications (in particular thumb collapse and metacarpophalangeal hyperextension), 3.31% moderate complications and 1.90% minor complications, leading to a 2.0% revision rate. 23.88% of prostheses had severe complications (loosening, dislocation and wear), 5.06% moderate complications and 1.36% minor complications, leading to a 12.8% revision rate. In addition, we analyzed more recent prosthesis designs separately, and found lower prevalence of severe complications (16.56%) and revision surgery (4.3%).
CONCLUSION: Revision surgery for trapeziometacarpal prostheses is usually only a standard trapeziectomy with the same follow-up as first-line trapeziectomy, whereas revision surgery for trapeziectomies is much more complex and the results are uncertain. For this reason, we would reserve total trapeziectomy for revision surgeries and patients with low functional demand for whom a second surgery is not desirable. Further studies could confirm this attitude, especially focusing on the latest generation of dual mobility implants.
The invention discloses a lentiviral vector which has a truncated cis-acting element, wherein the sequence of the truncated cis-acting element is shown as SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6 or SEQ ID NO. 8. The invention also discloses a lentiviral vector system based on the lentiviral vector, a host cell, an application and a transfection method.
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to \[\>=\] 50 percent \[%\] improvement on baseline Montgomery Asberg Depression Rating Scale \[MADRS\] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
In the hot compress group, the knee was wrapped with a bandage and the hot thermophor (approximately 40-45 °C) was placed on the knee. The hot thermoform was applied to the patient 3 days a week by keeping it for 20 minutes.
Bariatric surgery (also known as "weight loss surgery") is the most effective treatment for obesity as well as a number of other obesity-related conditions, including type 2 diabetes, hypertension, and hypercholesterolemia. Interestingly, not all patients respond with significant weight loss following surgery and some patients even lack much weight loss at all over the long-term. Even though variability in treatment response is observed in a variety of diseases, the biological basis for this variability in weight loss after bariatric surgery is poorly understood. Recent data from our group as well as others, however, suggest that differences in the total length of the small intestine may significantly contribute to these differences in weight loss over time. For example, Roux-en-Y gastric bypass is thought to exert its weight loss effect because of a bypass of small intestine that causes a degree of nutrient malabsorption. The bypassed small intestine (\<100cm) is near the proximal end of the intestines closest to the stomach. Hypothetically, an individual with the greater total small intestine length may not benefit as much from the bypass as someone who has a much shorter length of total small intestine. Whether or not this hypothetical relationship is true remains unknown, but a recent study demonstrated that small intestine length does differ significantly between individuals with lengths ranging from 300cm to \>1200cm. The total length of small intestine is not routinely measured during any bariatric procedure, as the lengths of the bypass limbs are determined from the portion of the intestines closest to the stomach. The purpose of this study is to determine whether the amount of total small intestine significantly affects weight loss in patients undergoing bariatric surgery - both the Roux-en-Y gastric bypass (RYGB) or the Vertical Sleeve Gastrectomy (VSG). If there is a significant effect of total small intestine length on long-term weight loss in bariatric patients, then it would justify the conduct of a further study to determine whether or not these operations should be performed differently in individuals to account for the differences in small intestine length. This is an observational study that will be looking at body weight (primary endpoint) and other nutritional endpoints (other pre-specified outcome measure) over time up to ten years in this patient cohort. The body weight measurements and any laboratory data will be collected that are part of the routine clinical care of these patients.
Fall prevention is the most important issue for the elderly. Due to the low cost and convenience of wearable devices, numerous techniques have been developed to detect falls in clinical environment. However, such effects with large populations have not been established for the elderly. Another, existing systems mainly focus on detecting a fall with little emphasis on fall prediction and prevention. There is an urgent need for developing monitoring systems that can detect near-falls and alert persons who suffer from subsequently falls. Therefore, investigators propose a project to study the clinical application of a fall detection and prevention system for reducing falls in the elderly.

The main objectives of the project are to develop the fall detection and prevention system and to investigate its effectiveness in preventing falls for the elderly. Eighty elderly will be recruited and randomly allocated into either the experimental or sham groups (n=40 for each group). Subjects in the experimental group will wear the fall detection and prevention system on the lower back. The system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events. In the sham group, subjects wear a sham system with record but no alert function. Both groups will receive the same treadmill walking training for 30 minutes per session, 3 sessions per week for 6 weeks. The outcome measures including falls, balance function, gait ability, physical activity, and quality of life will be assessed before intervention, after intervention, and at 6-months follow-up.

Fall-induced physiological and psychological consequences limit daily activities and reduce quality of life in the elderly. The proposed study innovates a system that not only detects but also alarms users to prevent falls. Moreover, quantitative measurement of such fall detection and prevention system will be investigated for the elderly in this project. This study provides practical and efficacy solutions to prevent falls for home and community settings.
Methods and systems for monitoring procedural compliance of staff in a facility. One or more defined procedure to be performed by staff in a room of the facility are stored in a memory. The defined procedure(s) may include one or more conditions that must be met for the procedure to be considered as performed correctly. The one or more conditions may include visiting a defined procedure location in the room. The location of the person in the room may be identified by triangulating one or more signals emitted by a device carried by the person and/or transmitting one or more signals into the room and receiving one or more corresponding reflected signals reflected off the person in the room. The method and/or system may determine whether the one or more conditions of the defined procedure have been met, and if not, issue an alert.
Raptiva administered by weekly subcutaneous injections. First dose of 0.7mg/kg. Subsequent doses will be of 1mg/kg SQ weekly.
The invention provides a method for the biological synthesis of nano-selenium by using silver-resistant Bacillus edaphicus and the application thereof. According to the technical scheme of the invention, a silver-resistant Bacillus edaphicus R5-41, which can tolerate the higher concentration of selenite and selenate, is separated from the soil. After that, the synthesis of biological nano-selenium is conducted by using the Bacillus edaphicus R5-41. The biological nano-selenium is subjected to separation and purification, and then the large-scale preparation of the biological nano-selenium is realized. The nano-selenium can be applied to the fields of fertilizers, feedstuffs, selenium-enriched functional foods, health-care products, medical products and the like. The nano-selenium is prepared through the biological fermentation process, so that the advantages of environmental friendliness, high yield, safety, high efficiency and the like are realized. The prepared biological nano-selenium can be applied to selenium-rich fertilizers and selenium-rich feedstuffs. After the fertilizing or feeding process of selenium-rich fertilizers and selenium-rich feedstuffs prepared by the biological nano-selenium, crops, melons,fruits, vegetables, meat, egg and milk are remarkable in selenium-rich effect.
Disclosed herein is a probiotic composition that includes  Lactobacillus salivarius  subsp.  salicinius  AP-32,  Lactobacillus johnsonii  MH-68, and  Bifidobacterium animalis  subsp.  lactis  CP-9, which are deposited at the China Center for Type Culture Collection (CCTCC) respectively under accession numbers CCTCC M 2011127, CCTCC M 2011128, and CCTCC M 2014588. A number ratio of  Lactobacillus salivarius  subsp.  salicinius  AP-32,  Lactobacillus johnsonii  MH-68, and  Bifidobacterium animalis  subsp.  lactis  CP-9 ranges from 1:0.1:0.1 to 1:1:8. Also disclosed herein is use of the probiotic composition for alleviating type 1 diabetes mellitus (T1DM).
Functional movement screening (FMS) was developed by Cook et al. It evaluates range of motion, muscular imbalances and core strength by means of seven different movement. It is used to analyze the pattern of various fundamental movements and then highlights the limitations in that pattern and recognizes asymmetries in relation to that pattern of movement and eventually compares these inadequacies with outcomes that will improve a pragmatic approach to injury prevention. Prior studies reported that during pre-participation FMS can predict injuries in various athletes.

Several research studies carried out by researchers in this area have been involved in the exploring the strategies that can enhance the efficiency and performance of footballers in the field and investigate the effects of injuries on performance. Studies including FMS as an injury and evaluation tool have subjects which includes athletes playing multiple sports and generally involved male footballers, but the studies comparing scores of FMS among female footballers with male footballers are scarce. With advances in society and knowledge of participation in sports, more women participate in sports events, and the pre-participation and injury of this particular population should be explored. This research will discover this particular issue and bring to light the needs of female footballers and contributes to recognizing FMS as a predictive method for injury.